Kerrie L McDonald
Overview
Explore the profile of Kerrie L McDonald including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1788
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sim H, Wachsmuth L, Barnes E, Yip S, Koh E, Hall M, et al.
Neurooncol Adv
. 2023 Oct;
5(1):vdad124.
PMID: 37841696
Background: There is an immunologic rationale to evaluate immunotherapy in the older glioblastoma population, who have been underrepresented in prior trials. The NUTMEG study evaluated the combination of nivolumab and...
2.
Basiri Z, Yang Y, Bruinsma F, Nowak A, McDonald K, Drummond K, et al.
Cancer Causes Control
. 2022 Feb;
33(5):749-757.
PMID: 35184245
Purpose: High-grade disease accounts for ~ 70% of all glioma, and has a high mortality rate. Few modifiable exposures are known to be related to glioma risk or mortality. Methods:...
3.
Noor H, Whittaker S, McDonald K
Genomics
. 2022 Feb;
114(2):110289.
PMID: 35124175
Notch signalling pathway, particularly its ligand delta-ligand 3 (DLL3), is important in glioma, however, little is known about DLL3 regulation and prognostic effects. Immunohistochemistry on a cohort of 163 gliomas...
4.
Noor H, Briggs N, McDonald K, Holst J, Vittorio O
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771529
Background: Identification of prognostic biomarkers in cancers is a crucial step to improve overall survival (OS). Although mutations in () is prevalent in astrocytoma, the prognostic effects of mutation are...
5.
Buck J, Dyer P, Hii H, Carline B, Kuchibhotla M, Byrne J, et al.
Front Mol Biosci
. 2021 May;
8:633344.
PMID: 33996894
Medulloblastoma is the most common malignant childhood brain tumor, and 5-year overall survival rates are as low as 40% depending on molecular subtype, with new therapies critically important. As radiotherapy...
6.
Sim H, McDonald K, Lwin Z, Barnes E, Rosenthal M, Foote M, et al.
Neuro Oncol
. 2021 May;
23(10):1736-1749.
PMID: 33984151
Background: Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies. This study evaluated whether veliparib, a brain-penetrant poly(ADP-ribose)...
7.
Bao G, Wang X, Xu R, Loh C, Adeyinka O, Pieris D, et al.
Cancers (Basel)
. 2021 Feb;
13(4).
PMID: 33557152
We have developed a platform, termed PathoFusion, which is an integrated system for marking, training, and recognition of pathological features in whole-slide tissue sections. The platform uses a bifocal convolutional...
8.
Lu V, Jue T, McDonald K
Sci Rep
. 2020 Oct;
10(1):18156.
PMID: 33097778
Glioblastoma (GBM) is a malignant brain tumour with a dismal prognosis, despite best treatment by surgical resection, radiation therapy (RT) and chemotherapy with temozolomide (TMZ). Nanoparticle (NP) therapy is an...
9.
Lu V, McDonald K
Nanomedicine (Lond)
. 2020 Sep;
15(22):2107-2117.
PMID: 32867588
To determine the biodistribution of lanthanum (III) oxide (LaO) nanoparticle (NP) therapy to the brain and its biocompatibility with radiation therapy (RT) and chemotherapy (CT). Healthy balb/c nude mice were...
10.
Gedye C, Sachchithananthan M, Leonard R, Jeffree R, Buckland M, Ziegler D, et al.
Neurooncol Pract
. 2020 Apr;
7(1):31-37.
PMID: 32257282
Background: A key component of cancer research is the availability of clinical samples with appropriately annotated clinical data. Biobanks facilitate research by collecting/storing various types of clinical samples for research....